Thierry Facon discusses the groundbreaking IMRO study – Media Medic

Media Medic posted on LinkedIn:

” Exciting Highlights from the European Hematology Association (EHA) Conference!
We’re thrilled to share an exclusive interview with Dr. Thierry Facon, who discusses the groundbreaking IMRO study. This research sets the isatuximab VRD protocol as the new standard for elderly multiple myeloma patients ineligible for transplantation. Discover how this innovative treatment improves safety and quality of life, thanks to global collaboration, including key contributions from Chinese clinical doctors. Don’t miss these significant advancements in hematology!”

Source: Media Medic/LinkedIn